Rexahn Pharmaceuticals Granted European Patent for Anti-cancer Compound RX-3117
22-Jan-2010 -
Rexahn Pharmaceuticals, Inc. announced that the European Patent Office has granted a patent for its novel anti-cancer compound, RX-3117.
"In addition to our co-development partnership with Teva, this European patent award further validates the commercial potential of RX-3117," said Dr. Chang ...
clinical trials
drug resistance
lung cancer
+4